ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Association of LncRNA PCBP1-AS1 with cancer occurrence and development: A review

Wu, Yanping; Mou, Jie; Liu, Yuling; Zheng, Wenfei*1
Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries2023-10-27DOI: 10.1097/MD.0000000000035631
9阅读
引用收藏
分享

摘要

Long-stranded noncoding RNAs (LncRNAs) are noncoding RNAs >200 nucleotides in length. Polycytidine binding protein 1 antisense LncRNA is abbreviated as LncRNA polycytosine binding protein 1 antisense1 (PCBP1-AS1). Since studies in recent years have revealed the importance of PCBP1-AS1 in human genetic analysis, it is an important member of the LncRNA family. Genetically engineered group analysis of PCBP1-AS1 regulates the progression of cancer in biology. Therefore, it may be an important RNA in the regulation of human cancer. This article summarizes the molecular mechanism and clinical role of PCBP1-AS1 in various tumor types. Taking "PCBP1-AS1" and "cancer" as keywords, this paper analyzed the relationship between PCBP1-AS1 and various tumors by searching PubMed and Geen Medical, and summarized the related regulatory mechanism of PCBP1-AS1. PCBP1-AS1 is a valuable tumor-associated LncRNA that plays different biological roles in different cancers. Overall, it can both promote and inhibit the development of cancer. For example, abnormally high expression in castration-resitant prostate cancer, hepatocellular carcinoma, cervical cancer, glioma, and colorectal cancer promotes the proliferation and progression of these cancers; in contrast, PCBP1-AS1 inhibits cancer proliferation, metastasis, invasion, and recurrence when highly expressed in vulvar squamous cell carcinoma, Hodgkin lymphoma, and lung adenocarcinoma. PCBP1-AS1 regulates the development of multiple tumors, and the specific mechanism needs to be further investigated, which may become a new tumor marker and potential therapeutic target.

学科与关键词

关键词
cancerlong noncoding RNAPCBP1-AS1regulationtherapeutic target
相关
加载中…
  • LncRNA SBF2-AS1: A Budding Star in Various Cancers
    Tan, Fangshun; Chen, Jinlan; Wang, Bei; Du, Zhuoying; Mou, Jie; Wu, Yinxin; Liu, Yuling; Zhao, Fangnan; Yuan, Chengfu*Current Pharmaceutical Design, 2022, 28(18): 1513-1522.被引 3
  • HNF1A-AS1: A Tumor-associated Long Non-coding RNA
    Liu, Yuling; Zhao, Fangnan; Tan, Fangshun; Tang, Lu; Du, Zhuoying; Mou, Jie; Zhou, Gang*; Yuan, Chengfu*Current Pharmaceutical Design, 2022, 28(21): 1720-1729.被引 4
  • Long Non-coding RNA DLGAP1-AS1 and DLGAP1-AS2: Two Novel Oncogenes in Multiple Cancers
    Zhao, Fangnan; Tan, Fangshun; Tang, Lu; Du, Zhuoying; Chen, Xiaoya; Yang, Yuzhi; Zhou, Gang*; Yuan, Chengfu*Current Medicinal Chemistry, 2023, 30(25): 2822-2834.
查看全部 →

发表信息

论文状态
公开发表
期刊
Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries
发表日期
2023-10-27
卷期
第 102 卷, 第 43 期
页码
e35631
DOI
10.1097/MD.0000000000035631
语言
ENGLISH
成果收录
SCIE

作者

  • W

    Wu, Yanping (第一作者)

    1 · china three gorges univ

  • M

    Mou, Jie

    1 · china three gorges univ

查看全部 4 位作者收起作者
  • L

    Liu, Yuling

    1 · china three gorges univ

  • Z

    Zheng, Wenfei (通讯)

    1 · china three gorges univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417